[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR093414A1 - Composicion conservante que consiste en un complejo de oxicloro estabilizado y un poliol, y composicion topica que la comprende - Google Patents

Composicion conservante que consiste en un complejo de oxicloro estabilizado y un poliol, y composicion topica que la comprende

Info

Publication number
AR093414A1
AR093414A1 ARP130104109A ARP130104109A AR093414A1 AR 093414 A1 AR093414 A1 AR 093414A1 AR P130104109 A ARP130104109 A AR P130104109A AR P130104109 A ARP130104109 A AR P130104109A AR 093414 A1 AR093414 A1 AR 093414A1
Authority
AR
Argentina
Prior art keywords
composition
polyol
stabilized
oxychlor
complex
Prior art date
Application number
ARP130104109A
Other languages
English (en)
Inventor
L Tien Walter
s graham Richard
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR093414A1 publication Critical patent/AR093414A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un conservante que consiste en un complejo de oxicloro estabilizado y un poliol que tiene de 3 a 6 átomos de carbono, y una composición tópica que lo comprende. Reivindicación 4: La composición de la reivindicación 3, caracterizada porque el poliol es glicerina. Reivindicación 5: La composición de la reivindicación 3, caracterizada porque el dióxido de cloro estabilizado es Purite®. Reivindicación 7: La composición de la reivindicación 6, caracterizada porque comprende además un agente terapéuticamente activo.
ARP130104109A 2012-11-08 2013-11-08 Composicion conservante que consiste en un complejo de oxicloro estabilizado y un poliol, y composicion topica que la comprende AR093414A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261723884P 2012-11-08 2012-11-08

Publications (1)

Publication Number Publication Date
AR093414A1 true AR093414A1 (es) 2015-06-03

Family

ID=49620311

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104109A AR093414A1 (es) 2012-11-08 2013-11-08 Composicion conservante que consiste en un complejo de oxicloro estabilizado y un poliol, y composicion topica que la comprende

Country Status (4)

Country Link
US (1) US20140127327A1 (es)
AR (1) AR093414A1 (es)
TW (1) TW201427690A (es)
WO (1) WO2014074605A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786538B2 (en) 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
IL92351A (en) * 1988-11-29 1994-02-27 Allergan Inc Irvine Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
CA2741288A1 (en) * 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
US20110294744A1 (en) * 2010-05-25 2011-12-01 Allergan, Inc. Cyclosporin emulsions

Also Published As

Publication number Publication date
TW201427690A (zh) 2014-07-16
WO2014074605A1 (en) 2014-05-15
US20140127327A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
MX363004B (es) Formulaciones desinfectantes tópicas y usos de las mismas.
MX2015013727A (es) Composicion para preparacion de uso externo con permeabilidad transdermica mejorada.
UY33598A (es) Imidazopiridazinas sustituidas
BR112014004460A2 (pt) material polimérico para um recipiente isolado
BR112013018352A2 (pt) composição de minociclina tópica e método
WO2015003360A3 (en) Therapeutically active compounds and their methods of use
NZ712270A (en) Pharmaceutical composition of s-ketamine hydrochloride
BR112014014832A2 (pt) formulação e método de controlar fungos
CL2015000051A1 (es) Una composicion farmaceutica acuosa estabilizada para almacenamiento a largo plazo que comprende etanercept y un estabilizante para prevenir, inhibir o reducir la presencia de particulas subvisibles en la composicion, donde el estabilizante comprende un tensioactivo, y donde la composicion esta libre de arginina como estabilizante.
NI201500118A (es) Imidazopiridazinas sustituidas
AR083775A1 (es) Composicion dentifrica con astringencia reducida
AR082155A1 (es) Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido
CL2014002591A1 (es) Composicion topica semisolida que comprende pirfenidona, dialil oxido de disulfuro modificado (odd-m), un agente gelificante y otros excipientes o aditivos; proceso para fabricarla; metodo de tratamiento; y su uso para eliminar, reducir o prevenir el acne.
WO2015003355A3 (en) Therapeutically active compounds and their methods of use
DOP2016000007A (es) Pirazolpiridinas sustituidas
AR081520A1 (es) Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
WO2013156488A3 (en) Optimised subcutaneous therapeutic agents
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
WO2011117378A3 (en) Compositions comprising brimonidine for the treatment of erythema
MX2015003074A (es) Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas.
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
EA201890212A1 (ru) Новое применение сульфата декстрана
IN2012DE00497A (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure